Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial.

Wu L, Gu L, Fan W, Wei M, Dai T, Li X, Xiao L, Li B, Tian D-S, Duan R, et al.

Nat Med. 2026 Aug 10. PMID: 42575985. Abstract